SF-AdEPT - Nye enzymer til bruk innen presisjonsterapi

Offentlig prosjektsammendrag

Messenger RNA (mRNA) has proved as a versatile vaccine platform during the COVID-19 Pandemic. ArcticZymes will with the SF-AdEPT project explore and develop the product portfolio to address the demand for novel enzyme tools for RNA analytics and manufacturing. Global implementation of RNA therapeutic technology suffers from considerable challenges regarding efficient manufacturing with required purity and scale to provide sufficient high quality compliant RNA products to meet the global demand. Enzymes are key components in biomanufacturing processes and the emerging market for therapeutic RNA creates a need for novel and improved enzymes, and a significant market opportunity for enzyme manufacturers, which ArcticZymes wishes to exploit to strengthen the position as a global enzyme supplier. The projectʼs main objective is to develop novel enzyme solutions enabling innovative workflows and cost-effective manufacturing and analytics of RNA therapeutics to improve human health.